IDEAYA Q3 2026 Earnings: Darovasertib NDA Submitted as Net Loss Widens

IDEAYA Biosciences (NASDAQ: IDYA) reported Q3 2026 collaboration revenue of $10.2 million, up from $8.9 million in Q2, while diluted net loss per share remained unchanged sequentially at $1.22. Net loss widened to $125.7 million as research, clinical development, personnel, and commercial preparation expenses increased, while cash and marketable securities declined to $1.15 billion. The quarter’s central pipeline event was the submission of the darovasertib-plus-crizotinib NDA for metastatic uveal melanoma.

Core Financial Results

The sequential revenue increase reflected research and development services performed under IDEAYA’s exclusive darovasertib license agreement with Servier. IDEAYA had $139.8 million of remaining performance obligations related to anticipated clinical development cost reimbursements, which will be recognized over time as services are completed.

Higher operating expenses more than offset the revenue increase. The release did not provide comparable Q3 2025 quarterly figures, so the table uses Q2 2026 as the comparison period.

Pipeline and Regulatory Progress

Darovasertib remained IDEAYA’s most advanced program. During Q3, the company completed its NDA submission to the FDA for darovasertib plus crizotinib in metastatic uveal melanoma under the Real-Time Oncology Review program. The submission supports potential approval but does not establish whether or when the FDA will approve the combination.

At ESMO 2026, IDEAYA presented data from OptimUM-01 and OptimUM-02. The latter showed a statistically significant improvement in median progression-free survival versus investigator’s choice in treatment-naïve, HLA-A*02:01-negative patients, according to both central and investigator assessments. An exact median PFS result was not included in the supplied release.

In primary uveal melanoma, follow-up data from approximately 119 patients in OptimUM-09 showed tumor shrinkage in more than 85% of patients. The reported eye-preservation rate was 57% in the enucleation cohort, while 74% to 79% of patients in the plaque brachytherapy cohort achieved a lower predicted radiation dose to critical eye structures. IDEAYA and Servier also initiated OptimUM-011, a roughly 450-patient Phase 3 adjuvant trial.

IDE849 was another significant program during the quarter. Data from Hengrui’s Phase 1 study in China showed median overall survival of 17.4 months in second-line small cell lung cancer. Among 19 patients with other neuroendocrine carcinomas, the overall response rate was 52.6%, the confirmed response rate was 36.8%, median PFS was 7.0 months, and the nine-month overall survival rate was 82.4%.

IDEAYA expects initial data from its own global Phase 1/2 IDE849 trial by the end of 2026 or early 2027. It also plans to begin two Phase 3 registrational trials by year-end, including a 400-patient extensive-stage small cell lung cancer study.

Elsewhere in the pipeline, IDEAYA initiated monotherapy expansion for IDE892 in MTAP-deleted solid tumors and began an IDE892-plus-IDE397 combination cohort. The company is also pursuing IDE892 combination studies through collaborations with Roche and Genentech.

Profitability, Cash, and Balance Sheet

R&D spending increased by $12.9 million sequentially, primarily because of higher clinical trial, development, and personnel costs. G&A expenses rose by $3.8 million as IDEAYA added personnel and prepared for the potential commercialization of darovasertib. Stock-based compensation was $17.7 million, compared with $16.7 million in Q2.

Although the net loss widened, loss per share remained at $1.22 because weighted-average diluted shares increased to 102.9 million from 92.1 million. Interest and other income of $11.9 million also partially offset the $137.6 million operating loss.

Cash, cash equivalents, and marketable securities declined by about $90 million during the quarter, primarily because of net cash used in operations. IDEAYA ended September with $1.15 billion in liquid resources, while total liabilities were $124.0 million.

OptimUM-010 Closure Frees $100-$125 Million for Other Programs

IDEAYA decided to stop enrollment and close the Phase 3 OptimUM-010 trial because of continued site activation and enrollment difficulties. The decision is expected to generate estimated savings of $100 million to $125 million.

Management plans to redirect those resources toward other pipeline priorities, including potential registrational studies for IDE849 and IDE892. For neoadjuvant darovasertib, the company instead intends to use published OptimUM-09 data to seek potential inclusion in clinical practice guidelines, which could support payer coverage for eligible U.S. patients if successful.

This reprioritization reduces spending on a trial facing execution challenges while preserving capital for other development programs. However, reliance on guideline inclusion is a different path from completing a Phase 3 study and remains subject to external review.

Guidance

IDEAYA reaffirmed its cash runway into 2030 based on the current operating plan. The company did not provide revenue or earnings guidance in the supplied release.

Recent Insider Transactions

The supplied six-month summary showed 35,888 shares purchased and 35,888 shares sold across two transactions in each direction, resulting in no net change. The recent transaction record also included derivative exercises and stock awards, which are distinct from open-market purchases and sales.

These records describe the transactions but do not, by themselves, establish insiders’ views about IDEAYA’s prospects.

Risks Investors Need to Watch

• Regulatory uncertainty: The darovasertib combination remains subject to FDA review, and an NDA submission does not ensure approval or determine the timing of a decision.
• Clinical data maturity: Several cited results came from early-stage studies, small patient groups, or subgroup analyses. Outcomes may change with longer follow-up or larger trials.
• Trial execution: The closure of OptimUM-010 demonstrates that site activation and enrollment problems can disrupt development plans even when clinical rationale remains intact.
• Rising expenses and cash use: R&D and G&A expenses both increased sequentially, contributing to a wider net loss and a roughly $90 million quarterly decline in cash resources.
• Operating-plan dependence: The runway into 2030 assumes IDEAYA’s current operating plan. Additional trials, commercialization spending, or changes in development priorities could alter that timeline.

Summary

IDEAYA’s Q3 2026 results reflected rising investment across clinical development and darovasertib commercial preparation, which widened the net loss despite higher collaboration revenue. The darovasertib NDA submission was the quarter’s most consequential milestone, while the closure of OptimUM-010 created expected savings for IDE849, IDE892, and other priorities. Investors’ next focus will be the FDA review, upcoming IDE849 data and Phase 3 execution, and whether the company can maintain its stated cash runway as spending expands.